Michalis Michael

995 total citations
22 papers, 492 citations indexed

About

Michalis Michael is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Michalis Michael has authored 22 papers receiving a total of 492 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Hematology and 7 papers in Molecular Biology. Recurrent topics in Michalis Michael's work include Multiple Myeloma Research and Treatments (6 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). Michalis Michael is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). Michalis Michael collaborates with scholars based in Greece, Cyprus and Australia. Michalis Michael's co-authors include David Goldstein, Efstathios Kastritis, Stephen Clarke, Meletios Α. Dimopoulos, Chee Khoon Lee, Dimitra Gika, B Iacopetta, Wei Chua, Paul Mitchell and Eirini Katodritou and has published in prestigious journals such as Blood, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Michalis Michael

21 papers receiving 482 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michalis Michael Greece 13 229 225 172 72 66 22 492
Merry Tetef United States 14 269 1.2× 147 0.7× 82 0.5× 119 1.7× 78 1.2× 29 581
Nishant Tageja United States 15 163 0.7× 188 0.8× 212 1.2× 29 0.4× 115 1.7× 33 516
Said Baidas United States 12 142 0.6× 189 0.8× 89 0.5× 125 1.7× 83 1.3× 22 442
Martin J. Auger United Kingdom 10 103 0.4× 200 0.9× 213 1.2× 36 0.5× 72 1.1× 17 470
Emma Guagnellini Italy 12 236 1.0× 186 0.8× 114 0.7× 93 1.3× 25 0.4× 21 693
A Fontana France 10 324 1.4× 133 0.6× 78 0.5× 89 1.2× 19 0.3× 25 505
Joseph Eid United States 10 199 0.9× 446 2.0× 304 1.8× 119 1.7× 49 0.7× 16 691
Wendy Goodspeed United States 12 129 0.6× 226 1.0× 61 0.4× 162 2.3× 69 1.0× 22 567
Faruk Taş Türkiye 15 235 1.0× 154 0.7× 38 0.2× 99 1.4× 18 0.3× 44 585
Lola Luo United States 8 113 0.5× 128 0.6× 164 1.0× 69 1.0× 80 1.2× 8 403

Countries citing papers authored by Michalis Michael

Since Specialization
Citations

This map shows the geographic impact of Michalis Michael's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michalis Michael with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michalis Michael more than expected).

Fields of papers citing papers by Michalis Michael

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michalis Michael. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michalis Michael. The network helps show where Michalis Michael may publish in the future.

Co-authorship network of co-authors of Michalis Michael

This figure shows the co-authorship network connecting the top 25 collaborators of Michalis Michael. A scholar is included among the top collaborators of Michalis Michael based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michalis Michael. Michalis Michael is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gavriatopoulou, Maria, Ioannis Ntanasis‐Stathopoulos, Emmanouil Spanoudakis, et al.. (2025). Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström’s Macroglobulinemia. Clinical Lymphoma Myeloma & Leukemia. 25(10). e818–e825.e2.
2.
3.
Papadopoulos, Antonios N., et al.. (2013). Formaldehyde in Indoor Air of New Appartments in Drama, Greece. 2(2). 1 indexed citations
4.
Dimopoulos, Meletios Α., Sosana Delimpasi, Eirini Katodritou, et al.. (2013). Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Annals of Oncology. 25(1). 195–200. 109 indexed citations
5.
6.
Symeonidis, Argiris, Efstathios Kastritis, Sosana Delimpasi, et al.. (2013). Multiple Myeloma Patients ≤40 Years Of Age: Clinical Characteristics and Outcome In The Era Of Novel Agents. Blood. 122(21). 3226–3226. 1 indexed citations
7.
Dimopoulos, Meletios Α., Sosana Delimpasi, Eirini Katodritou, et al.. (2012). Significant Improvement of the Survival of Patients with Multiple Myeloma Presenting with Severe Renal Impairment After the Introduction of Novel Agents. Blood. 120(21). 948–948. 1 indexed citations
8.
Dimopoulos, Meletios Α., Efstathios Kastritis, Eurydiki Michalis, et al.. (2011). The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients’ renal function. Annals of Oncology. 23(3). 722–729. 19 indexed citations
9.
Kastritis, Efstathios, Μαρία Ρούσσου, Michalis Michael, et al.. (2010). High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients. British Journal of Haematology. 150(5). 587–591. 9 indexed citations
10.
Michael, Michalis, Efstathios Kastritis, Evridiki Michalis, et al.. (2010). Clinical Characteristics and Outcome of Primary Systemic Light-Chain Amyloidosis in Greece. Clinical Lymphoma Myeloma & Leukemia. 10(1). 56–61. 14 indexed citations
11.
Corcoran, Niall M., Christopher M. Hovens, Michalis Michael, Mark Rosenthal, & Anthony J. Costello. (2010). Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. British Journal of Cancer. 103(4). 462–468. 47 indexed citations
12.
Chua, Wei, David Goldstein, Chee Khoon Lee, et al.. (2009). Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. British Journal of Cancer. 101(6). 998–1004. 78 indexed citations
13.
Psarra, Katerina, Violetta Kapsimali, Konstantinos Liapis, et al.. (2009). Distinct neutrophil subpopulations phenotype by flow cytometry in myelodysplastic syndromes. Leukemia & lymphoma. 50(3). 401–409. 8 indexed citations
14.
Michael, Michalis, et al.. (2009). Development of Multiple Myeloma in a Patient with Chronic Myeloid Leukemia While on Treatment with Imatinib Mesylate for 65 Months. The Oncologist. 14(12). 1198–1200. 15 indexed citations
15.
Khan, Omar, Michalis Michael, Ian Olver, et al.. (2008). A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. British Journal of Cancer. 98(10). 1614–1618. 45 indexed citations
16.
Goldstein, David, Guy van Hazel, Euan Walpole, et al.. (2007). Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. British Journal of Cancer. 97(4). 464–471. 31 indexed citations
17.
Goldstein, David, Paul Mitchell, Michalis Michael, et al.. (2005). Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. British Journal of Cancer. 92(5). 832–837. 19 indexed citations
18.
Ioachim, E., et al.. (2005). A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. British Journal of Urology. 95(4). 655–659. 37 indexed citations
19.
Michael, Michalis, A. Wirth, Michael MacManus, et al.. (2005). A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC. British Journal of Cancer. 93(6). 652–661. 12 indexed citations
20.
Michael, Michalis, et al.. (1997). Phase I Dose Intensification Study of 2-Weekly Epirubicin with GM-CSF in Advanced Cancer. American Journal of Clinical Oncology. 20(3). 259–262. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Merry Tetef Breakdown of academic impact, for papers by Nishant Tageja Breakdown of academic impact, for papers by Said Baidas Breakdown of academic impact, for papers by Martin J. Auger Breakdown of academic impact, for papers by Emma Guagnellini Breakdown of academic impact, for papers by A Fontana Breakdown of academic impact, for papers by Joseph Eid Breakdown of academic impact, for papers by Wendy Goodspeed Breakdown of academic impact, for papers by Faruk Taş Breakdown of academic impact, for papers by Lola Luo
Rankless by CCL
2026